Fatty liver disease (MASLD/MASH) trials in Israel
5 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
- Where
- Afula, Haifa, Jerusalem, Nahariya, Nazareth, Petah Tikva, Ramat Gan, Tel Aviv
- Age
- 18 years to 80 years
- People
- 1,650 worldwide
- Run by
- Akero Therapeutics, Inc
See details and how to joinNCT06215716 - Phase 3Taking peopleA Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- Where
- Afula, Beersheba, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv
- Age
- 18 years to 80 years
- People
- 1,350 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- Where
- Afula, Beersheba, Haifa, Jerusalem, Nahariya, Petah Tikva, Tel Aviv, Tel HaShomer
- Age
- 18 years to 75 years
- People
- 1,800 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00 - Phase 3Taking peopleA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Where
- Afula, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv
- Age
- 18 years to 80 years
- People
- 2,150 worldwide
- Run by
- Akero Therapeutics, Inc
See details and how to joinNCT06528314 - Phase 3Taking peopleA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Where
- Ashkelon, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
- Age
- 18 years and over
- People
- 4,500 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00